Taking the stress out of managing gout.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 2793228)

Published in Can Fam Physician on December 01, 2009

Authors

Tessa Laubscher1, Zack Dumont, Loren Regier, Brent Jensen

Author Affiliations

1: Academic Family Medicine at University of Saskatchewan in Saskatoon.

Articles cited by this

Uric acid and cardiovascular risk. N Engl J Med (2008) 12.20

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ (2006) 7.80

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA (2006) 7.27

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 6.36

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.59

Pathogenesis of gout. Ann Intern Med (2005) 4.50

Alcohol intake and risk of incident gout in men: a prospective study. Lancet (2004) 4.12

Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ (2008) 3.71

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet (2008) 3.59

British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) (2007) 3.39

Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med (2007) 3.22

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med (1984) 3.05

Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol (2007) 2.71

Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med (2008) 2.32

A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf (2008) 2.24

Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med (1987) 2.17

Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem (2007) 2.10

Gout: an update. Am Fam Physician (2007) 1.90

NSAID use and progression of chronic kidney disease. Am J Med (2007) 1.75

Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis (2000) 1.52

Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol (2004) 1.52

Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med (2005) 1.50

Vitamin C intake and the risk of gout in men: a prospective study. Arch Intern Med (2009) 1.33

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis (2008) 1.31

Diagnosis and management of gout. BMJ (2006) 1.29

Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum (2007) 1.24

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum (2004) 1.24

Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol (1997) 1.20

Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis (2008) 1.10

Pathophysiology, clinical presentation and treatment of gout. Drugs (2006) 1.06

Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol (1988) 1.02

Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum (2001) 1.00

Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol (1999) 0.98

Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol (1993) 0.96

Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology (Oxford) (2007) 0.96

Systemic corticosteroids for acute gout. Cochrane Database Syst Rev (2008) 0.95

Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med (1995) 0.94

A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther (2004) 0.93

Management of recurrent gout. BMJ (2008) 0.90

Educational program to improve the dosage prescribing of allopurinol. Med J Aust (1995) 0.81

Sugary drinks, fruit, and increased risk of gout. BMJ (2008) 0.77

Articles by these authors

Opioids for chronic noncancer pain in the elderly: an osteoarthritis case. Can Fam Physician (2011) 0.88

Rate versus rhythm control in atrial fibrillation. Can Fam Physician (2013) 0.86

Taking the stress out of acne management. Can Fam Physician (2009) 0.83

A brief overview of academic detailing in Canada: Another role for pharmacists. Can Pharm J (Ott) (2012) 0.82

Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in chronic heart failure. Ann Intern Med (2005) 0.78

Behaviour management in dementia. Can Fam Physician (2011) 0.77

Diabetes in the frail elderly: individualization of glycemic management. Can Fam Physician (2012) 0.77

Taking the stress out of individualizing ADHD drug therapy. Can Fam Physician (2009) 0.75

Retrospective analysis of opioid medication incidents requiring administration of naloxone. Can J Hosp Pharm (2013) 0.75

Targeting success in heart failure: evidence-based management. Can Fam Physician (2010) 0.75

Pharmacologic management of essential tremor. Can Fam Physician (2010) 0.75

Taking the stress out of treating erectile dysfunction. Can Fam Physician (2010) 0.75

Taking the stress out of insulin initiation in type 2 diabetes mellitus. Can Fam Physician (2009) 0.75

Navigating the complexity of ulcerative colitis: challenging case example. Can Fam Physician (2011) 0.75

Approach to the management of idiopathic hirsutism. Can Fam Physician (2012) 0.75

Funding for continuing medical education. CMAJ (2008) 0.75

Drug comparison charts. Detailed, objective, comparative drug information. Can Fam Physician (2004) 0.75